OBSV
Closed
Obseva Sa
0.083
-0.001 (-1.19%)
Last Update: 21 Apr 2023 16:30:00
Yesterday: 0.084
Day's Range: 0.079 - 0.0923
Send
sign up or login to leave a comment!
When Written:
0.0927
ObsEva SA is a Swiss biopharmaceutical company that focuses on developing and commercializing novel therapies for women's reproductive health and pregnancy-related complications. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva's lead product candidate, linzagolix, is a potential treatment for endometriosis and uterine fibroids. The company is also developing a pipeline of other product candidates, including a potential treatment for preterm labor.
ObsEva has partnerships with several pharmaceutical companies, including Takeda Pharmaceuticals and Yuyuan BioScience Technology Co., Ltd. The company went public on the NASDAQ stock exchange in January 2018.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
ObsEva's lead product candidate, linzagolix, is a potential treatment for endometriosis and uterine fibroids. The company is also developing a pipeline of other product candidates, including a potential treatment for preterm labor.
ObsEva has partnerships with several pharmaceutical companies, including Takeda Pharmaceuticals and Yuyuan BioScience Technology Co., Ltd. The company went public on the NASDAQ stock exchange in January 2018.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
0.0927
ObsEva SA is a biopharmaceutical company that focuses on developing and commercializing novel therapies for women's reproductive health and pregnancy. The company was founded in 2012 and is headquartered in Geneva, Switzerland. ObsEva's pipeline includes potential treatments for conditions such as endometriosis, uterine fibroids, preterm labor, and infertility. The company's lead product candidate, linzagolix, is being developed for the treatment of endometriosis and uterine fibroids. ObsEva is also developing a potential treatment for preterm labor called nolasiban. The company has partnerships with pharmaceutical companies such as Kissei, Yuyu Pharma, and MSD Switzerland.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








